Morgan Stanley’s SOLAZYME INC COM STK (DE) SZYM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q2 | – | Sell |
-330,728
| Closed | -$672K | – | 6899 |
|
|
2016
Q1 | $672K | Buy |
330,728
+201,744
| +156% | +$360K | ﹤0.01% | 4235 |
|
|
2015
Q4 | $320K | Sell |
128,984
-33,344
| -21% | -$98.9K | ﹤0.01% | 4828 |
|
|
2015
Q3 | $422K | Sell |
162,328
-155,876
| -49% | -$406K | ﹤0.01% | 4705 |
|
|
2015
Q2 | $1M | Buy |
318,204
+147,251
| +86% | +$505K | ﹤0.01% | 4196 |
|
|
2015
Q1 | $489K | Sell |
170,953
-106,247
| -38% | -$272K | ﹤0.01% | 4667 |
|
|
2014
Q4 | $715K | Sell |
277,200
-441,482
| -61% | -$1.93M | ﹤0.01% | 4413 |
|
|
2014
Q3 | $5.36M | Sell |
718,682
-23,016
| -3% | -$215K | ﹤0.01% | 2584 |
|
|
2014
Q2 | $8.74M | Buy |
741,698
+89,207
| +14% | +$951K | ﹤0.01% | 2161 |
|
|
2014
Q1 | $7.58M | Buy |
652,491
+115,756
| +22% | +$1.36M | ﹤0.01% | 2186 |
|
|
2013
Q4 | $5.84M | Sell |
536,735
-5,973
| -1% | -$58.8K | ﹤0.01% | 2434 |
|
|
2013
Q3 | $5.85M | Buy |
542,708
+3,771
| +0.7% | +$43K | ﹤0.01% | 2263 |
|
|
2013
Q2 | $6.32M | Buy |
+538,937
| New | +$5.38M | ﹤0.01% | 2106 |
|
Morgan Stanley's SZYM Position: Q2 2016 in Review
Morgan Stanley sold out of SOLAZYME INC COM STK (DE) (SZYM) in Q2 2016, closing a stake of 330,728 shares — an estimated $672K sold.
Morgan Stanley first reported a position in SZYM in Q2 2013 and held it in 12 quarters. The position peaked at $8.74M in Q2 2014. 0 funds tracked by Wall St. Rank hold SZYM as of Q2 2016.
- Morgan Stanley reported no remaining SOLAZYME INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
- Morgan Stanley sold 330,728 SOLAZYME INC COM STK (DE) shares in Q2 2016, an estimated $672K.
- Morgan Stanley first reported a position in SOLAZYME INC COM STK (DE) in Q2 2013 and held it in 12 quarters.
- Morgan Stanley's SOLAZYME INC COM STK (DE) position peaked at $8.74M in Q2 2014.
- 0 funds tracked by Wall St. Rank held SOLAZYME INC COM STK (DE) as of Q2 2016.
Based on Morgan Stanley's 13F filing for Q2 2016, filed 12 Aug 2016.